Eliem Therapeutics Inc. and Tenet Medicines Inc., a development-stage private biotechnology company, have entered into a definitive acquisition agreement whereby Eliem has agreed to acquire Tenet.   The combined company plans to focus on advancing Tenet’s lead product candidate TNT119, a potentially best-in class anti-CD19 antibody, designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy.   In support of th...